Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases.
$2.87-1.37%
报价 2026-11-13
市值
$235.6M
EV
$350.2M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -73.0%
$2.63$10.63
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| LXEOLexeo Therapeutics, Inc. Common Stock | $235.6M | -1.4% | -100.0% | 0% | – | – | – | |
| SLNSilence Therapeutics plc | $936.6M | +0.2% | – | 51% | – | – | – | |
| CAPRCapricor Therapeutics, Inc. | $551.9M | -6.9% | +7442.9% | 0% | – | 0.6x | – | |
| CTNMContineum Therapeutics, Inc. Class A Common Stock | $348.6M | +0.8% | -28.3% | 0% | – | – | – | |
| KYTXKyverna Therapeutics, Inc. | $319.3M | +0.4% | +86.6% | 0% | – | – | – | |
| LRMRLarimar Therapeutics, Inc. | $313.7M | +11.9% | – | 0% | – | – | – | |
| DBVTDBV Technologies S.A. | $263.5M | -3.6% | – | -110.7% | – | – | – | |
| VNDAVanda Pharmaceuticals Inc. | $241.3M | +1.0% | +20.3% | 93.2% | – | – | – | |
| AMRNAmarin Corporation plc | $235.4M | -2.5% | – | 65.7% | – | – | – | |
| 同行中位数 | – | – | +53.5% | 0% | – | 0.6x | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。